|
Originally published In Press as doi:10.1074/jbc.M105823200 on September 4, 2001
J. Biol. Chem., Vol. 276, Issue 45, 41748-41754, November 9, 2001
Inhibition of Protein Translocation across the Endoplasmic
Reticulum Membrane by Sterols*
IngMarie
Nilsson §,
Henna
Ohvo-Rekilä¶ ,
J.
Peter
Slotte¶ ,
Arthur E.
Johnson§**, and
Gunnar
von
Heijne 
From the Department of Biochemistry and Biophysics,
Stockholm University, SE-106 91 Stockholm, Sweden, the
¶ Department of Biochemistry and Pharmacy, Åbo Akademi
University, P. O. Box 66, FIN-20521 Turku, Finland, and the
§ Department of Medical Biochemistry and Genetics, Texas
A & M University System Health Science Center, College
Station, Texas 77843-1114
Received for publication, June 22, 2001, and in revised form, August 24, 2001
 |
ABSTRACT |
Cholesterol and related sterols are known to
modulate the physical properties of biological membranes and can affect
the activities of membrane-bound protein complexes. Here, we report
that an early step in protein translocation across the endoplasmic
reticulum (ER) membrane is reversibly inhibited by cholesterol
levels significantly lower than those found in the plasma membrane. By
UV-induced chemical cross-linking we further show that high cholesterol
levels prevent cross-linking between ribosome-nascent chain complexes
and components of the Sec61 translocon, but have no effect on
cross-linking to the signal recognition particle. The inhibiting effect
on translocation is different between different sterols. Our data
suggest that the protein translocation machinery may be sensitive to
changes in cholesterol levels in the ER membrane.
 |
INTRODUCTION |
Sterols are known to modulate the physical properties of
biological membranes (1-4). In particular, cholesterol increases the
orientational order and reduces the rate of motion of the phospholipid
hydrocarbon chains (1-3) and decreases the effective free volume in
the membrane (5). The induced changes in membrane properties can help
to modulate the activity of membrane-resident proteins, in addition to
more specific protein regulation mechanisms (2, 6). Cholesterol can
further affect the function of individual proteins by direct binding
(7-9). Since cholesterol increases the lipid chain order, the
insertion of cholesterol leads to a laterally more condensed membrane
(1-4). Cholesterol/sphingolipid rafts and caveolae in the plasma
membranes are good examples of such tightly packed, laterally
segregated cholesterol-rich domains (4, 10, 11). Raft-like structures
have also been suggested to exist in the Golgi and in the endocytic
pathway, while the endoplasmic reticulum
(ER)1 and other internal
membranes are devoid of rafts (12).
Cholesterol levels differ markedly between different cellular
membranes. The cholesterol concentration is low in the ER and increases
throughout the secretory pathway. Most of the cellular cholesterol is
found in the plasma membrane (13-16). The fact that the ER membrane
contains only small amounts of cholesterol (13, 17, 18) is quite
amazing, since it is the site of cholesterol biosynthesis,
esterification, and regulation (19, 20). All of the regulatory proteins
residing in the ER respond to changes in the local cholesterol level.
Changes in plasma membrane cholesterol are reflected in the ER
cholesterol levels, allowing feedback control of cholesterol synthesis
and esterification in the ER (20-22).
Given that membrane-bound ER resident enzymes normally function in a
cholesterol-poor environment, they may be expected to be particularly
sensitive to increases in cholesterol levels. Here we report that an
early step in protein translocation across the ER membrane is
reversibly inhibited by cholesterol levels significantly lower than
those found in the plasma membrane. We have also examined whether a
change in cholesterol double bond position or number affects protein
translocation. 5 -Cholestan-3 -ol (dihydrocholesterol) and
4-cholesten-3 -ol (allocholesterol) inhibit protein translocation,
whereas 4-cholesten-3-one (cholestenone), 7(5 )-cholesten-3 -ol
(lathosterol), and 8(14)-cholesten-3 -ol (8-sterol) have no apparent
effects. By UV-induced chemical cross-linking we further show that high
cholesterol levels prevent cross-linking between ribosome-nascent chain
complexes (RNCs) and components of the Sec61 translocon, but have no
effect on cross-linking of RNCs to the signal recognition particle
(SRP).
These observations suggest that an increase in membrane stiffness
renders the Sec61 protein translocation machinery in the ER unable to
recognize and/or initiate translocation of nascent polypeptide chains.
One possible implication of our findings is that Sec61 translocons that
have leaked out to the Golgi compartment and beyond (23) may be
rendered nonfunctional by cholesterol-mediated inhibition.
 |
MATERIALS AND METHODS |
Enzymes and Chemicals--
Unless otherwise stated, all enzymes,
plasmid pGEM1, and rabbit reticulocyte lysate were from Promega
(Madison, WI) or New England Biolabs (Boston, MA). T7 DNA
polymerase, [35S]Met, 14C-methylated marker
proteins, ribonucleotides, deoxyribonucleotides, dideoxyribonucleotides, the cap analogues m7G(5')ppp(5')G and G(5')ppp(5')G, and [14C]oleoyl-coenzyme A (56 mCi/mmol) were from Amersham Pharmacia Biotech (Uppsala, Sweden and
Piscataway, NJ). Protein A-Sepharose, puromycin, and 7-methylguanosine
5'-monophosphate were from Sigma. Affinity-purified rabbit antisera to
the C-terminal 13 amino acids of TRAM were obtained from Research
Genetics (Huntsville, AL). Most of the sterols used and
methyl- -cyclodextrin were obtained from Sigma. Allocholesterol was
purchased from Steraloids (Newport, RI) and 8-sterol from Research Plus
Inc. (Bayonne, NJ). The purity of all sterols was examined by reversed
phase high performance liquid chromatography, and all, except for
dihydrocholesterol, were 99% pure and were used without further
purification. Dihydrocholesterol was purified by crystallization in
ethanol-water at 20 °C overnight and was shown to be 99% pure by
reversed phase high performance liquid chromatography. Dog pancreas
microsomes were prepared as described in Ref. 24.
DNA Manipulations--
Site-specific mutagenesis was performed
according to the method of Kunkel (25, 26). All mutants were confirmed
by sequencing of plasmid DNA. All cloning steps were done according to
standard procedures.
Lep Expression Plasmid--
For cloning into and expression of
Lep from the pGEM1 plasmid, the 5' end of the lep gene was
modified, first, by the introduction of an XbaI site and,
second, by changing the context 5' to the initiator ATG codon to a
"Kozak consensus" sequence (27). Thus, the 5' region of the gene
was modified to: ...
ATAACCCTCTAGAGCCACCATGGCGAAT ...
(XbaI site and initiator codon underlined). Mutants of Lep
were cloned into pGEM1 behind the SP6 promoter as an
XbaI-SmaI fragment.
Expression in Vitro--
DNA template for in vitro
transcription of full-length Lep mRNA was prepared by transcription
of the Lep-pGEM1 plasmid with SP6 RNA polymerase for 1 h at
37 °C. The transcription mixture was as follows: 1-5 µg of DNA
template, 5 µl of 10× SP6 H-buffer (400 mM Hepes-KOH pH
7.4, 60 mM magnesium acetate, 20 mM spermidine HCl), 5 µl of bovine serum albumin (1 µg/µl), 5 µl of
m7G(5')ppp(5')G (10 mM), 5 µl of dithiothreitol
(50 mM), 5 µl of NTP mix (10 mM ATP,
10 mM CTP, 10 mM UTP, 5 mM GTP),
18.5 µl of H2O, 1.5 µl of RNase inhibitor (40 units/µl), 0.5 µl of SP6 RNA polymerase (20 units/µl).
Translation of 1 µl of Lep mRNA in 9 µl of nuclease-treated reticulocyte lysate, 1 µl of RNase inhibitor (40 units/µl), 1 µl
of [35S]Met (10 µCi/µl), 1 µl of amino acids mix (1 mM concentration of each amino acid except Met), 1 µl of
mRNA, 1 µl of dog pancreas microsomes (2 units/µl; one unit is
defined as the amount of microsomes required for 50% translocation of
in vitro synthesized preprolactin) was performed as
described in Ref. 28 at 30 °C for 1 h.
Template for in vitro transcription of truncated Lep
mRNA was prepared using PCR to amplify a fragment from the
Lep-pGEM1 plasmid. The 5' primer was situated 210 bases upstream of the translation start, and the amplified fragment thus contained the SP6
transcriptional promoter from pGEM1. The 3' primer was chosen to
produce a truncated fragment ending at codon 271 in Lep, and no stop
codon was included. Translation/translocation reactions of truncated
Lep mRNA for puromycin treatment (Fig. 3, panel B) were
performed at 22 °C in a total volume of 14 µl. When relevant, 3.5 µg of cholesterol (0.23 µg/µl) was added after 25-min
translation. After an additional 10-min incubation, 1.9 µl of
potassium acetate (4 M), 1.5 µl of magnesium acetate (20 mM), and 1.5 µl of puromycin (30 mM) were
added, and the incubation was continued at 22 °C for another 10 min.
For alkali extraction, a 10-µl translation mix was diluted with 90 µl of ice-cold 0.1 M Na2CO3/NaOH,
pH 11.5, and the samples were centrifuged for 10 min at 70,000 rpm in a
Beckman tabletop 100.3 rotor. Before SDS-PAGE, the supernatants were
precipitated with trichloroacetic acid, and all samples were heated at
95 °C for 5 min.
Proteins were analyzed by SDS-PAGE, and gels were visualized on a Fuji
FLA-3000 phosphoimager using the Fuji Image Reader 8.1j software.
UV-induced Cross-linking and Immunoprecipitation--
mRNA
coding for truncated preprolactin polypeptide was synthesized by
in vitro transcription using linearized pSPBP4 DNA and SP6
RNA polymerase as described previously (29). The
PvuII restriction site (after codon 86) was chosen to obtain
a run-off transcript encoding the N-terminal 86 residues of
preprolactin. In vitro translation for photolysis (25 µl
total volume) and immunoprecipitation (50 µl total volume) were done
in wheat germ cell-free extract (29, 30) in the presence of 40 nM canine SRP, 8 equivalents (16 equivalents for
immunoprecipitation) of column-washed rough microsomes (24),
[35S]Met (5 µCi for cross-linking, 100 µCi for
immunoprecipitation), and 15 pmol of ANB-Lys-tRNA (29).
Photoreactive N -(5-azido-2-nitrobenzoyl)-Lys-tRNA
( ANB-Lys-tRNA) was prepared as detailed previously (31). Samples
were photolysed on ice for 15 min using a 500-watt mercury arc lamp
(29). After photolysis, membranes or ribosomes were sedimented through
a sucrose cushion in a Beckman airfuge at 4 °C for 5 min, 20 p.s.i. and 60 min, 30 p.s.i., respectively.
Microsome and ribosome pellets were resuspended in buffer (100 mM Tris-HCl, pH 7.6) containing detergent (0.25% w/v SDS
for Sec61 - and Sec61 -specific antibodies and 1% w/v SDS for
TRAM- and SRP54-specific antibodies) and placed at 55 °C for a
minimum of 30 min. The volume was increased with buffer A (140 mM NaCl, 10 mM Tris-HCl, pH 7.6, 2% v/v Triton
X-100, 0.2% w/v SDS) for Sec61 and Sec61 antibodies and buffer B
(150 mM NaCl, 50 mM Tris-HCl, pH 7.6, 2% (v/v)
Triton X-100, 0.2% SDS) for TRAM and SRP54 antibodies. Samples were
then precleared by rocking with protein A-Sepharose at room temperature
for 1 h before the Sepharose beads were removed by sedimentation.
Sec61 -, Sec61 -, TRAM-, or SRP54-specific antiserum was added to
each supernatant, and the samples were rocked overnight at 4 °C.
Protein A-Sepharose was then added to each sample and incubated for a
minimum of 2 h at 4 °C. The immunoprecipitated proteins were
analyzed by SDS-PAGE and visualized using a Bio-Rad GS-250
phosphorimager (29).
Addition of Sterols to Microsomes--
To enrich the microsomes
with cholesterol or sterol analogues, complexes between
methyl- -cyclodextrin (CyD) and sterols were prepared by a slight
modification of the procedure described in Ref. 32. 32 mg of CyD was
dissolved in 1 ml of MS buffer (0.25 M sucrose, 20 mM Hepes-KOH, pH 7.5), and this solution was added to a
thin film of sterol (1 mg) in a tube. The molar ratio of sterol to CyD
was 1/10. The mixture was sonicated in a bath sonicator for 20 min.
Translation mixes including microsomes were incubated with various
amounts of sterol in the form of sterol-CyD complexes during the
translation/translocation assay. Sterol-CyD complexes were added to the
translation mix together with mRNA and microsomes at the beginning
of the incubation, unless otherwise stated.
Analysis of Microsomal Lipids--
Microsomes were extracted
with hexane/2-propanol (3/2, v/v) and water, and again with hexane, to
obtain the total lipids. The organic phase was then collected and
evaporated to dryness. The extracted lipids were applied on a high
performance thin layer chromatography plate and eluted with
chloroform:methanol:water (25:10:1.1 by volume) to separate the
phospholipid classes. The phospholipids were visualized by staining
with cupric acetate (3%, w/v and 8% H3PO4,
w/v) and heating the plates for 15 min at 150 °C to develop the
color and identified from standards run in parallel. The absorbance of
the lipid spots was determined with a scanning densitometer (Camag TLC
Scanner 3). The amount of sphingomyelin in the microsomal preparation
was calculated from the absorbance data compared with a sphingomyelin
standard series.
The amount of cholesterol in the microsomal membranes was analyzed from
the total lipid extract by gas-liquid chromatography (Shimadzu GC-14A).
Epicoprostanol was added as an internal standard to the samples. The
cholesterol amount in the sample was calculated compared with a
standard sample with known cholesterol concentration. The samples were
injected on a SacTM-5 column (0.25-µm film, 0.25 mm × 30 m, Supelco) with the inlet block at 260 °C and separated
on the column with a temperature program of
6 °C·min 1 from 260 to 280 °C. The samples were
detected with a flame ionization detector at 300 °C.
The amount of sphingomyelin and cholesterol in the microsomal
preparation was calculated relative to the protein concentration in the
microsomes. The protein concentration in the sample was determined by
the method of Lowry (33), using bovine serum albumin as standard.
Measurement of Cholesterol in Microsomes Using ACAT--
The
cholesterol measurements were done by an ACAT assay as described in
Ref. 18. In vitro translations were done in reticulocyte lysate in the presence of rough microsomes and cholesterol-CyD complexes or unloaded CyD. After translation the microsomes were sedimented in a Beckman tabletop centrifuge (4 °C, 70 K, 10 min, 100.3 rotor). The pellet was resuspended in MS buffer containing dithiothreitol (1 mM), bovine serum albumin (1 mg/ml), and [14C]oleoyl-coenzyme A (30 µM)
and incubated at 37 °C for 60 min to allow ACAT to esterify
cholesterol residing in the ER fraction. After incubation, microsomes
were sedimented, the enzyme was inactivated, and cholesterol esters
were measured. Briefly, microsomal lipids were extracted with
hexane/2-propanol (3/2 v/v), the solvent was evaporated, and the lipids
were re-dissolved in hexane/2-propanol. The lipid samples were applied
on normal phase thin layer chromatography plates and separated with
hexane/diethyl ether/acetic acid (130/30/2 v/v/v). Lipid spots were
visualized by staining with iodine and identified from standards run in
parallel. The cholesterol ester spots were cut into scintillation vials
and counted for radioactivity with a LKB Rack-Beta liquid scintillation counter.
 |
RESULTS |
Cholesterol Reversibly Inhibits Protein Translocation across the
Microsomal Membrane--
To study the effect of cholesterol on protein
translocation across the ER membrane, rough dog pancreas microsomes
were incubated with different amounts of methyl- -cyclodextrin
(CyD)-bound cholesterol in an in vitro protein translocation
assay. As shown in Fig. 1, N-glycosylation of the C-terminal P2 domain of the model
membrane protein leader peptidase (Lep, panel A) was
completely blocked by 0.10 µg/µl cholesterol (panel B).
Addition of cyclodextrin (Cyd) alone had no effect
(panel B, lane 3).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
Addition of cholesterol
(Chol) to rough microsomes blocks protein
translocation as assayed by N-glycosylation.
A, the Lep model protein. The Asn215-Glu-Thr
glycosylation acceptor site in the lumenal P2 domain is indicated by Y. B, in vitro translation of Lep in the absence
( ) and presence (+) of rough dog pancreas microsomes (RM)
with addition of different amounts of CyD-cholesterol. CyD-cholesterol
was added to the translation mix at the same time as the mRNA and
microsomes. Glycosylated (black dot) and nonglycosylated
(white dot) molecules are indicated. C, alkaline
extraction of Lep translated in the presence of microsomes and in the
absence or presence of Cyd-cholesterol (0.13 µg/µl cholesterol, 4.0 µg/µl CyD). T, total sample before extraction;
P, pellet; S, supernatant.
|
|
To ascertain that the inhibition of glycosylation was caused by an
inhibition of translocation rather than an effect on the oligosaccharyltransferase, microsomes were subjected to alkaline extraction to assay for membrane integration of Lep (Fig. 1,
panel C). In the absence of cholesterol, essentially all
glycosylated molecules remained in the alkali-resistant membrane pellet
(P), whereas most of the molecules were found in the
supernatant (S) when translation was carried out in the
presence of cholesterol.
Finally, translocation of Lep was also assayed by signal peptide
cleavage. For this, a construct with a signal peptidase cleavage site
at the C-terminal end of an engineered H2 segment was used (the H2
sequence was ... KKKKL14VPSAQA+A ... where the
"+" sign indicates the signal peptidase cleavage site; see Ref. 34)
(Fig. 2, panel A). Again,
translocation was completely inhibited in microsomes that were exposed
to 0.10 µg/µl cholesterol (panel B).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 2.
Addition of cholesterol
(Chol) to rough microsomes blocks protein
translocation as assayed by signal peptide cleavage. A,
the Lep-derived model protein (Lep-CC) with a signal peptidase cleavage
cassette introduced near the lumenal end of the H2 transmembrane
segment (34). B, in vitro translation of Lep-CC
in the absence ( ) and presence (+) of rough dog pancreas microsomes
(RM) with addition of different amounts of CyD-cholesterol.
Cleaved (squares) and uncleaved (dots)
glycosylated (black) and nonglycosylated (white)
molecules are indicated.
|
|
The reversibility of the cholesterol-dependent inhibition
of translocation was tested by first preincubating microsomes at 30 °C for 20 min with an inhibiting concentration of cholesterol (0.10 µg/µl) followed by a second preincubation for 20 min with an
excess of uncomplexed cyclodextrin to extract cholesterol back from the
microsomal membranes. The treated microsomes (including the added CyD
and cholesterol) were then used in a normal in vitro protein
translocation assay. As shown in Fig. 3,
a concentration of 5.2 µg/µl uncomplexed cyclodextrin in the second
preincubation was sufficient to restore the translocation activity,
showing that the inhibiting effect of cholesterol is reversible.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 3.
Excess unloaded CyD restores translocation
activity when added to cholesterol-loaded microsomes. Rough
microsomes were first incubated with CyD-cholesterol (0.10 µg/µl
cholesterol (Chol)) for 20 min at 30 °C and then
incubated with the indicated concentrations of unloaded CyD for an
additional 20 min at 30 °C to re-extract cholesterol from the
microsomes. The treated microsomes were then used together with Lep
mRNA in a standard in vitro translocation assay.
Glycosylated (black dot) and nonglycosylated (white
dot) molecules are indicated.
|
|
To better define the step at which cholesterol exerts its inhibiting
effect, we used Lep mRNA truncated at codon 271 (56 residues downstream of the glycosylation site) to produce nonglycosylated, translocon-bound RNCs, and then checked whether addition of cholesterol could still block full translocation (as assayed by glycosylation) after release of the nascent chain by treatment with puromycin and high
salt (35). As shown in Fig. 4, released
nascent chains became glycosylated both in the absence (lane
5) and presence (lane 7) of cholesterol, albeit
somewhat less efficiently in the latter case. It is unlikely that the
cholesterol did not have time to equilibrate between the CyD-bound form
and the microsomal membranes during the 10-min incubation preceding the
addition of puromycin/high salt, since translocation of full-length Lep is efficiently blocked even when cholesterol is added together with Lep
mRNA to the translation/translocation mix (Fig. 1). Since translation was carried out at 22 °C in this experiment rather than
at 30 °C as is the experiments using full-length Lep mRNA, we
also ascertained that translocation of full-length Lep was completely
blocked when the same concentration of CyD-cholesterol as used with the
truncated chains (0.23 µg/µl cholesterol) was included in the
standard in vitro translation reaction at 22 °C (data not
shown).

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 4.
Cholesterol (Chol) does not
block translocation of nascent chains released from membrane-bound
RNCs. Lep mRNA truncated at codon 271 was incubated in the
standard translation/translocation mix for 25 min at 22 °C, followed
by a second incubation for 10 min either in the presence (+) or absence
( ) of CyD-cholesterol (0.23 µg/µl cholesterol). Finally, the
microsomes were incubated with puromycin/high salt
(pur/salt) for 10 min to release the nascent chains
(lanes 5-7). Glycosylated (black dot) and
nonglycosylated (white dot) molecules are indicated. The
schematic shows the nonglycosylated, membrane-bound RNC and the
glycosylated, puromycin-released form of the protein.
|
|
We conclude that cholesterol has at best a marginal effect on
translocation through the Sec61 translocon per se and thus
that the main inhibition must be at an earlier step in the
translocation pathway.
Cholesterol Levels in the Microsomal Membranes--
Since the
microsomal preparations used also contain varying levels of
contaminating membranes (the sphingomyelin and unesterified cholesterol
levels in the preparation were, respectively, 1.4 ± 0.05 nmol and
1.8 ± 0.05 nmol per mg of protein, suggesting some contamination
by plasma membranes, endosomal membranes, and possibly by some Golgi
membranes), the cholesterol levels in the ER-derived microsomes cannot
be assessed by simply measuring overall cholesterol in the membrane
fraction. Instead, an assay originally developed by Lange and Steck was
used (18), in which ER cholesterol is specifically esterified by the ER
enzyme ACAT. Cholesterol levels were measured both in nontreated
microsomes and in microsomes incubated with 2 µg of CyD-cholesterol
and were found to be increased 3.7-fold in the treated sample (mean of
three experiments; data not shown). Since the typical cholesterol level
in the ER is about 0.2% of total cellular unesterified cholesterol
(18), this suggests that the ER membranes in the treated microsomes
contained maximally 0.8% of cellular free cholesterol equivalent.
Thus, the amount of cholesterol in the ER membranes in the
cholesterol-loaded microsomes is much less than the amount of
cholesterol found in the plasma membrane. Depending on the cell type
and assay method used, cellular plasma membranes have been reported to
contain between 40 and 90% of the total cellular unesterified
cholesterol (13-16). Golgi membranes contain an intermediate level of
cholesterol as compared with ER and the plasma membrane (36, 37).
Cholesterol is asymmetrically distributed within the Golgi, with
greater amounts of cholesterol found in the portion of the Golgi
located near the plasma membrane than in the Golgi located near the
endoplasmic reticulum (37). Compilation of published estimates
of lipid content in various organelles suggest that whereas the
cholesterol/phospholipid molar ratio in ER membranes is 0.08 or less,
it is about 0.16 in Golgi membranes (38). However, these values differ
in cells from different tissues (see e.g. Ref. 39), so a
direct comparison is difficult to make. Nevertheless, considering that
the cholesterol-loaded microsomes in our preparations contain the
equivalent of only 1% of the cellular free cholesterol, the
cholesterol concentration of ER membranes in the loaded microsomes is
most likely lower than the amount of cholesterol found in Golgi membranes.
We conclude that cholesterol blocks protein translocation across
microsomal membranes at a concentration that is similar to its
concentration in the Golgi and significantly lower than in the plasma membrane.
Cholesterol Inhibits Nascent Chain Cross-linking to Components of
the Sec Translocon but Not to SRP--
To further characterize the
cholesterol-dependent inhibition of translocation, we used
UV-inducible cross-linking to probe the interaction between RNCs and
components of the translocation machinery. RNCs were prepared by
translation of truncated mRNAs encoding the first 86 residues of
the secretory model protein preprolactin (pPL). Lysyl-tRNAs carrying a
modified ANB-lysine residue were added to the translation mix to
incorporate the photoreactive ANB-Lys probe in place of lysine at
positions 4, 9, 72, and 78 in pPL (Fig.
5, panel A). The
pPL-86-nascent chain is long enough to be efficiently targeted to the
Sec61 translocon in the microsomal membrane, but is too short for
signal peptide cleavage to take place (40, 41).

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 5.
Cross-linking of truncated
preprolactin-ribosome-nascent chains complexes (pPL86-RNC) to
components of the translocation machinery. A, the
pPL86-RNC used. Approximate positions of ANB-Lys residues are
indicated by *. B, photocross-linking was induced by UV
exposure of pPL86-RNC complexes produced in the absence ( ) or
presence (+) of rough dog pancreas microsomes incubated either without
( ) or with (+) CyD-cholesterol (0.14 µg/µl cholesterol
(Chol)). Translation was carried out in wheat germ lysate in
the presence of 40 nM canine SRP. The samples in
lanes 9 and 10 were immunoprecipitated with a
SRP54 antiserum before SDS-PAGE. C, same as in panel
B, except that Sec61 and TRAM antisera were used for
immunoprecipitations. Molecular weight markers were included in
lane 1 as indicated. The star-marked band in
lane 2 is Sec61 -pPL86, c.f. panel
D. D, same as in panel B, except that a
Sec61 antiserum was used for immunoprecipitation.
|
|
As shown in Fig. 5, panel B, when translated in the absence
of microsomes, pPL-86 can be efficiently cross-linked to SRP both in
the presence and absence of 0.14 µg/µl of added cholesterol (lanes 4 and 5). When microsomes are present,
cross-linking to SRP is only seen in the presence of added cholesterol
(lane 9 versus lane 10). In contrast,
cross-linking to the translocon components Sec61 (panel
C, lanes 4 and 5), TRAM (panel C,
lanes 6 and 7), and Sec61 (panel D,
lanes 4 and 5) is only seen in the absence of
added cholesterol (the band just above Sec61 photoadduct in
panel C, lanes 2 and 4, probably
results from nascent chain cross-linking to Sec61 at two different
sites, as has been observed previously (42)). In a separate control
experiment, we verified that CyD alone (4.9 µg/µl) did not inhibit
cross-linking of pPL-86 to either Sec61 , TRAM, or SRP (data not shown).
We conclude that cholesterol does not affect the interaction between
RNCs and SRP, but efficiently prevents targeting of RNCs to the Sec61
translocon in the microsomal membrane.
Inhibiting Effects of Other Sterols on Protein
Translocation--
It has been established that sterol analogues
having altered double bond position or number can be added to L-cell
mouse fibroblasts without significant cellular toxicity
(43-45). Still, a number of enzymes involved in lipid
homeostasis are sensitive to the structure of cholesterol, for example
CTP:phosphocholine cytidylyltransferase and ACAT (47-49). Based on
this knowledge we wanted to examine whether altering the cholesterol
double bond structure would affect protein translocation. We thus
tested the inhibiting effect on protein translocation of a set of other
sterols (dihydrocholesterol, cholestenone, lathosterol,
allocholesterol, and 8-sterol, Fig. 6,
panel A) in the same way as had been done for cholesterol. Of these sterols, lathosterol and dihydrocholesterol have been detected
in animal cells, while allocholesterol, cholestenone, and 8-sterol, to
our knowledge, are purely synthetic (50, 51). Dihydrocholesterol and
allocholesterol inhibited translocation of Lep at roughly the same
concentrations as did cholesterol (Fig. 6, panel B, whereas
cholestenone, lathosterol, and 8-sterol had no effect up to the highest
concentration tested (0.22 µg/µl).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 6.
Not all sterols block protein
translocation. A, structures of the sterols tested.
B, as in Fig. 1, panel B, but with addition of
the indicated concentrations of sterol in the form of CyD-sterol
complexes (Chol, cholesterol; DHC,
dihydrocholesterol; CHN, cholestenone; LTH,
lathosterol; Allo, allocholesterol; 8-STE,
8-sterol). The amount of CyD is 1.1 µg/µl in the lanes with 0.03 µg/µl sterol and 7.1 µg/µl in lane 3 and in the
lanes with 0.22 µg/µl sterol.
|
|
 |
DISCUSSION |
To be able to maintain a high concentration of cholesterol in the
plasma membrane, the transport pathways for both newly synthesized and
lipoprotein-derived cholesterol are directed toward the cell surface
(52-55). The amount of cholesterol that can be solubilized in the
plasma membrane has been shown to depend on the sphingomyelin content
(56-58). When the solubilization capacity of the plasma membrane is
exceeded, cholesterol is transported from the plasma membrane to the ER
for esterification by ACAT (19, 59). Low density
lipoprotein-derived cholesterol can also be transported directly
from lysosomes to the ER by a pathway that is independent of the plasma
membrane (16). Cholesterol transport from the plasma membrane to the ER
seems to occur by a different mechanism than the transport of newly
synthesized cholesterol from the ER back to the plasma membrane, but
the mechanism for this transport is not yet clearly defined (60). The
transport has been suggested to be mediated by a "classical"
vesicular pathway or by a novel energy-independent vesicular transport
mechanism (16, 61, 62). Caveolae have also been suggested to play an
important role in cholesterol transport (16, 63-65). The pool of
cholesterol esters in the ER is in rapid equilibrium with the
regulatory pool of free cholesterol in the cell through the activity of
neutral cholesterol esterase, so that the level of free cholesterol in the cell is maintained constant (64).
It seems likely that the modulation of ER cholesterol levels controls
the activity of various regulatory elements of cholesterol homeostasis
located in the ER (55). A small increase in the level of plasma
membrane cholesterol above a critical threshold increases the transfer
of cholesterol to the ER and signals the control proteins to reduce the
amount of free cholesterol in the cell (66). The regulatory elements in
the ER include enzymes of sterol biosynthesis, ACAT, and a family of
transcription factor precursors called sterol regulatory
element-binding proteins that control the expression of other
regulatory elements (20, 22, 67).
Cholesterol is known to decrease the effective free volume available
for molecular motion in the hydrophobic core of lipid bilayers (5), and
this change in membrane properties has been shown to affect the
function of proteins residing in the membrane (6, 68, 69). Possibly,
some ER proteins need free volume in the membrane to be able to undergo
conformational changes upon activation and therefore can sense the
cholesterol-induced changes in the properties of the ER.
In this study, we have found that cholesterol reversibly inhibits an
early step in protein translocation across the microsomal membrane when
present at a concentration that is similar to its concentration in the
Golgi and significantly lower than in the plasma membranes of
eukaryotic cells. The effect seems to be specific for sterols that can
interact with phospholipids and decrease the free volume of the
membrane (cholesterol, dihydrocholesterol, and allocholesterol), since
cholestenone does not inhibit the translocation reaction (Fig. 6). It
is well accepted that cholestenone represents a membrane-inactive
steroid and that it cannot order phospholipid acyl chains to the extent
that cholesterol does (70, 71). Lathosterol and 8-sterol also do not
significantly inhibit the translocation reaction. Both of them have
been shown to order membranes to a lesser extent than cholesterol (50).
It is interesting that lathosterol behaves differently than
cholesterol, allocholesterol, and dihydrocholesterol, because of these
sterols only lathosterol is unable to activate membrane-bound
CTP:phosphocholine cytidylyltransferase (49). The different effect of
lathosterol on cytidylyltransferase as compared with the other sterols
used in the study was suggested to be caused by the inability of
lathosterol to stabilize the lamellar-to-hexagonal phase transition of
the membrane bilayer (49). Unfortunately, 8-sterol was not included in
that study.
As shown by photocross-linking using truncated pPL-nascent chains,
cholesterol does not inhibit the interaction between ribosome-nascent chain complexes and SRP, but fully blocks the interaction between ribosome-nascent chain complexes and components of the translocon (Fig.
5). Furthermore, truncated Lep-nascent chain translocation intermediates can be fully translocated across the microsomal membrane
and glycosylated when released from the ribosome by treatment with
puromycin-high salt even in the presence of cholesterol (Fig. 4).
Cholesterol thus exerts its effect either at the level of the
interaction between SRP and the SRP receptor or at the level of binding
of ribosome-nascent chain complexes to the translocon itself, but does
not inactivate the translocon once targeting has been completed. The
translocon-induced, SRP receptor subunit -mediated release of the
signal sequence from SRP may be a key step in this regard
(46).
At present, we can only speculate on the biological relevance of these
findings. One interesting possibility is that cholesterol-mediated inhibition of protein translocation may be a way to inactivate translocon complexes that have leaked out of the ER (23). Another possibility is that the inhibition may be important under conditions when increased plasma membrane cholesterol increases ER cholesterol levels (18, 59). In any case, our results show that the protein translocation machinery in mammalian cells is well adapted to its
normal low cholesterol environment in the ER membrane.
 |
ACKNOWLEDGEMENTS |
We gratefully thank Brian Mosteller, Yiwei
Miao, and Yuanlong Shao for excellent technical assistance and Peter J. McCormick and Stephanie Etchells for advice. Dog pancreas microsomes
were a kind gift from Dr. M. Sakaguchi, Fukuoka, Japan, and rabbit antibodies against canine SRP54 were a kind gift from Dr. B. Dobberstein, Heidelberg, Germany.
 |
FOOTNOTES |
*
This work was supported by grants from the Swedish Cancer
Foundation and the Swedish Research Council (to G. v. H.) and by grants
from the Swedish Research Council and the Swedish Foundation for
International Cooperation in Research and Higher Education (to I. M. N.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Both authors supported by grants from the Academy of Finland,
the Sigfrid Juselius Foundation, the Borg Foundation, the Magnus Ehrnrooth Foundation, the Walter and Lisi Wahl Foundation, the Medicinska Understödsföreningen Liv och Hälsa
Foundation, and from the Åbo Akademi University.
**
Supported by National Institutes of Health Grant GM 26494 and by
The Robert A. Welch Foundation.

To whom correspondence should be addressed. Tel.:
46-8-16-25-90; Fax: 46-8-15-36-79; E-mail:
gunnar@dbb.su.se.
Published, JBC Papers in Press, September 4, 2001, DOI 10.1074/jbc.M105823200
 |
ABBREVIATIONS |
The abbreviations used are:
ER, endoplasmic reticulum;
ACAT, acyl-coenzyme A:cholesterol
acyltransferase;
allocholesterol, 4-cholesten-3 -ol;
cholestenone, 4-cholesten-3-one;
cholesterol, 5-cholesten-3 -ol;
CyD, methyl- -cyclodextrin;
dihydrocholesterol, 5 -cholestan-3 -ol;
lathosterol, 7(5 )-cholesten-3 -ol;
8-sterol, 8(14)-cholesten-3 -ol;
ANB-Lys, N -(5-azido-2-nitrobenzoyl)lysine;
RNC, ribosome-nascent
chain complex;
SRP, signal recognition particle;
PAGE, polyacrylamide
gel electrophoresis;
pPL, protein preprolactin.
 |
REFERENCES |
| 1.
|
Yeagle, P. L.
(1985)
Biochim. Biophys. Acta
822,
267-287[Medline]
[Order article via Infotrieve]
|
| 2.
|
Yeagle, P. L.
(1988)
in
Biology of Cholesterol
(Yeagle, P. L., ed)
, pp. 121-146, CRC Press Inc., Boca Raton, FL
|
| 3.
|
Finegold, L.
(1993)
Cholesterol in Membrane Models
, CRC Press Inc., Boca Raton, FL
|
| 4.
|
Simons, K.,
and Ikonen, E.
(2000)
Science
290,
1721-1726[Abstract/Free Full Text]
|
| 5.
|
Straume, M.,
and Litman, B. J.
(1987)
Biochemistry
26,
5121-5126[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Yeagle, P. L.
(1991)
Biochimie (Paris)
73,
1303-1310[Medline]
[Order article via Infotrieve]
|
| 7.
|
Murata, M.,
Peranen, J.,
Schreiner, R.,
Wieland, F.,
Kurzchalia, T. V.,
and Simons, K.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10339-10343[Abstract/Free Full Text]
|
| 8.
|
Osborne, T. F.,
and Rosenfeld, J. M.
(1998)
Curr. Opin. Lipidol.
9,
137-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Lange, Y.,
and Steck, T. L.
(1998)
Curr. Opin. Struct. Biol.
8,
435-439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Simons, K.,
and Ikonen, E.
(1997)
Nature
387,
569-572[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Brown, D. A.,
and London, E.
(2000)
J. Biol. Chem.
275,
17221-17224[Free Full Text]
|
| 12.
|
Brown, D. A.,
and London, E.
(1998)
J. Membr. Biol.
164,
103-114[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Lange, Y.,
Swaisgood, M. H.,
Ramos, B. V.,
and Steck, T. L.
(1989)
J. Biol. Chem.
264,
3786-3793[Abstract/Free Full Text]
|
| 14.
|
Van Meer, G.
(1989)
Annu. Rev. Cell Biol.
5,
247-275[CrossRef]
|
| 15.
|
Lange, Y.
(1991)
J. Lipid Res.
32,
329-339[Abstract]
|
| 16.
|
Liscum, L.,
and Munn, N. J.
(1999)
Biochim. Biophys. Acta
1438,
19-37[Medline]
[Order article via Infotrieve]
|
| 17.
|
Lange, Y.,
Strebel, F.,
and Steck, T. L.
(1993)
J. Biol. Chem.
268,
13838-13843[Abstract/Free Full Text]
|
| 18.
|
Lange, Y.,
and Steck, T. L.
(1997)
J. Biol. Chem.
272,
13103-13108[Abstract/Free Full Text]
|
| 19.
|
Reinhart, M. P.,
Billheimer, J. T.,
Faust, J. R.,
and Gaylor, J. L.
(1987)
J. Biol. Chem.
262,
9649-9655[Abstract/Free Full Text]
|
| 20.
|
Brown, M. S.,
and Goldstein, J. L.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11041-11048[Abstract/Free Full Text]
|
| 21.
|
Lange, Y.,
and Steck, T. L.
(1994)
J. Biol. Chem.
269,
29371-29374[Abstract/Free Full Text]
|
| 22.
|
Brown, M. S.,
and Goldstein, J. L.
(1997)
Cell
89,
331-340[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Greenfield, J.,
and High, S.
(1999)
J. Cell Sci.
112,
1477-1486[Abstract]
|
| 24.
|
Walter, P.,
and Blobel, G.
(1983)
Methods Enzymol.
96,
84-93[Medline]
[Order article via Infotrieve]
|
| 25.
|
Kunkel, T. A.
(1987)
Methods Enzymol.
154,
367-382[Medline]
[Order article via Infotrieve]
|
| 26.
|
Geisselsoder, J.,
Witney, F.,
and Yuckenberg, P.
(1987)
BioTechniques
5,
786-791
|
| 27.
|
Kozak, M.
(1989)
Mol. Cell. Biol.
9,
5073-5080[Abstract/Free Full Text]
|
| 28.
|
Liljeström, P.,
and Garoff, H.
(1991)
J. Virol.
65,
147-154[Abstract/Free Full Text]
|
| 29.
|
Do, H.,
Falcone, D.,
Lin, J.,
Andrews, D. W.,
and Johnson, A. E.
(1996)
Cell
85,
369-378[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Liao, S.,
Lin, J.,
Do, H.,
and Johnson, A.
(1997)
Cell
90,
31-41[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Krieg, U. C.,
Walter, P.,
and Johnson, A. E.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
8604-8608[Abstract/Free Full Text]
|
| 32.
|
Christian, A. E.,
Haynes, M. P.,
Phillips, M. C.,
and Rothblat, G. H.
(1997)
J. Lipid Res.
38,
2264-2272[Abstract]
|
| 33.
|
Lowry, O. H.,
Rosebrough, N. J.,
Farr, A. L.,
and Randall, R. J.
(1951)
J. Biol. Chem.
193,
265-275[Free Full Text]
|
| 34.
|
Nilsson, I.,
Whitley, P.,
and von Heijne, G.
(1994)
J. Cell Biol.
126,
1127-1132[Abstract/Free Full Text]
|
| 35.
|
Whitley, P.,
Nilsson, I. M.,
and von Heijne, G.
(1996)
J. Biol. Chem.
271,
6241-6244[Abstract/Free Full Text]
|
| 36.
|
Colbeau, A.,
Nachbaur, J.,
and Vignais, P. M.
(1971)
Biochim. Biophys. Acta
249,
462-492[Medline]
[Order article via Infotrieve]
|
| 37.
|
Orci, L.,
Montesano, R.,
Meda, P.,
Malaisse-Lagae, F.,
Brown, D.,
Perrelet, A.,
and Vassalli, P.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
293-297[Abstract/Free Full Text]
|
| 38.
|
van Meer, G.
(1998)
Trends Cell Biol.
8,
29-33[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Brügger, B.,
Sandhoff, R.,
Wegehingel, S.,
Gorgas, K.,
Malsam, J.,
Helms, J. B.,
Lehmann, W. D.,
Nickel, W.,
and Wieland, F. T.
(2000)
J. Cell Biol.
151,
507-518[Abstract/Free Full Text]
|
| 40.
|
Crowley, K. S.,
Reinhart, G. D.,
and Johnson, A. E.
(1993)
Cell
73,
1101-1115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Krieg, U. C.,
Johnson, A. E.,
and Walter, P.
(1989)
J. Cell Biol.
109,
2033-2043[Abstract/Free Full Text]
|
| 42.
|
Plath, K.,
Mothes, W.,
Wilkinson, B. M.,
Stirling, C. J.,
and Rapoport, T. A.
(1998)
Cell
94,
795-807[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Rothblat, G. H.,
and Buchko, M. K.
(1971)
J. Lipid Res.
12,
647-652[Abstract]
|
| 44.
|
Rujanavech, C.,
and Silbert, D. F.
(1986)
J. Biol. Chem.
261,
7196-7203[Abstract/Free Full Text]
|
| 45.
|
Clejan, S.,
Bittman, R.,
and Rottem, S.
(1981)
Biochemistry
20,
2200-2204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Fulga, T.,
Sinning, I.,
Dobberstein, B.,
and Pool, M.
(2001)
EMBO J.
20,
2338-2347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Tavani, D. M.,
Nes, W. R.,
and Billheimer, J. T.
(1982)
J. Lipid Res.
23,
774-781[Abstract]
|
| 48.
|
Billheimer, J. T.
(1985)
Methods Enzymol.
111,
286-293[Medline]
[Order article via Infotrieve]
|
| 49.
|
Leppimäki, P.,
Mattinen, J.,
and Slotte, J. P.
(2000)
Eur. J. Biochem.
267,
6385-6394[Medline]
[Order article via Infotrieve]
|
| 50.
|
Ranadive, G. N.,
and Lala, A. K.
(1987)
Biochemistry
26,
2426-2431[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Urich, K.
(1994)
Comparative Animal Biochemistry
, pp. 624-656, Springer-Verlag, Berlin
|
| 52.
|
Lange, Y.,
and Matthies, H. J.
(1984)
J. Biol. Chem.
259,
14624-14630[Abstract/Free Full Text]
|
| 53.
|
Kaplan, M. R.,
and Simoni, R. D.
(1985)
J. Cell Biol.
101,
446-453[Abstract/Free Full Text]
|
| 54.
|
Johnson, W. J.,
Chacko, G. K.,
Phillips, M. C.,
and Rothblat, G. H.
(1990)
J. Biol. Chem.
265,
5546-5553[Abstract/Free Full Text]
|
| 55.
|
Lange, Y.,
Ye, J.,
and Chin, J.
(1997)
J. Biol. Chem.
272,
17018-17022[Abstract/Free Full Text]
|
| 56.
|
Kudchodkar, B. J.,
Albers, J. J.,
and Bierman, E. L.
(1983)
Atherosclerosis
46,
353-367[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Slotte, J. P.,
and Bierman, E. L.
(1988)
Biochem. J.
250,
653-658[Medline]
[Order article via Infotrieve]
|
| 58.
|
Okwu, A. K.,
Xu, X. X.,
Shiratori, Y.,
and Tabas, I.
(1994)
J. Lipid Res.
35,
644-655[Abstract]
|
| 59.
|
Xu, X. X.,
and Tabas, I.
(1991)
J. Biol. Chem.
266,
17040-17048[Abstract/Free Full Text]
|
| 60.
|
Field, F. J.,
Born, E.,
Murthy, S.,
and Mathur, S. N.
(1998)
J. Lipid Res.
39,
333-343[Abstract/Free Full Text]
|
| 61.
|
Skiba, P. J.,
Zha, X.,
Maxfield, F. R.,
Schissel, S. L.,
and Tabas, I.
(1996)
J. Biol. Chem.
271,
13392-13400[Abstract/Free Full Text]
|
| 62.
|
Zha, X.,
Pierini, L. M.,
Leopold, P. L.,
Skiba, P. J.,
Tabas, I.,
and Maxfield, F. R.
(1998)
J. Cell Biol.
140,
39-47[Abstract/Free Full Text]
|
| 63.
|
Smart, E. J.,
Ying, Y.,
Donzell, W. C.,
and Anderson, R. G.
(1996)
J. Biol. Chem.
271,
29427-29435[Abstract/Free Full Text]
|
| 64.
|
Fielding, C. J.,
and Fielding, P. E.
(1997)
J. Lipid Res.
38,
1503-1521[Abstract]
|
| 65.
|
Fielding, C. J.,
and Fielding, P. E.
(2000)
Biochim. Biophys. Acta
1529,
210-222[Medline]
[Order article via Infotrieve]
|
| 66.
|
Lange, Y.,
Ye, J.,
Rigney, M.,
and Steck, T. L.
(1999)
J. Lipid Res.
40,
2264-2270[Abstract/Free Full Text]
|
| 67.
|
Brown, M. S.,
and Goldstein, J. L.
(1998)
Nutr. Rev.
56,
S1-S3[Medline]
[Order article via Infotrieve]
|
| 68.
|
Straume, M.,
and Litman, B. J.
(1988)
Biochemistry
27,
7723-7733[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Mitchell, D. C.,
Straume, M.,
Miller, J. L.,
and Litman, B. J.
(1990)
Biochemistry
29,
9143-9149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 70.
|
Ben-Yashar, V.,
and Barenholz, Y.
(1989)
Biochim. Biophys. Acta
985,
271-278[Medline]
[Order article via Infotrieve]
|
| 71.
|
Lau, W. F.,
and Das, N. P.
(1995)
Experientia (Basel)
51,
731-737
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
I. Albrecht, J. Gatfield, T. Mini, P. Jeno, and J. Pieters
Essential role for cholesterol in the delivery of exogenous antigens to the MHC class I-presentation pathway
Int. Immunol.,
May 1, 2006;
18(5):
755 - 765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Karamyshev, D. J. Kelleher, R. Gilmore, A. E. Johnson, G. von Heijne, and I. Nilsson
Mapping the Interaction of the STT3 Subunit of the Oligosaccharyl Transferase Complex with Nascent Polypeptide Chains
J. Biol. Chem.,
December 9, 2005;
280(49):
40489 - 40493.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, M. Ge, L. Ciani, G. Kuriakose, E. J. Westover, M. Dura, D. F. Covey, J. H. Freed, F. R. Maxfield, J. Lytton, et al.
Enrichment of Endoplasmic Reticulum with Cholesterol Inhibits Sarcoplasmic-Endoplasmic Reticulum Calcium ATPase-2b Activity in Parallel with Increased Order of Membrane Lipids: IMPLICATIONS FOR DEPLETION OF ENDOPLASMIC RETICULUM CALCIUM STORES AND APOPTOSIS IN CHOLESTEROL-LOADED MACROPHAGES
J. Biol. Chem.,
August 27, 2004;
279(35):
37030 - 37039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ohashi, N. Mizushima, Y. Kabeya, and T. Yoshimori
Localization of Mammalian NAD(P)H Steroid Dehydrogenase-like Protein on Lipid Droplets
J. Biol. Chem.,
September 19, 2003;
278(38):
36819 - 36829.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Higgins, B. R. Berridge, B. J. Mills, A. E. Schultze, H. Gao, G. H. Searfoss, T. K. Baker, and T. P. Ryan
Gene Expression Analysis of the Acute Phase Response Using a Canine Microarray
Toxicol. Sci.,
August 1, 2003;
74(2):
470 - 484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Romisch, N. Collie, N. Soto, J. Logue, M. Lindsay, W. Scheper, and C.-H. C. Cheng
Protein translocation across the endoplasmic reticulum membrane in cold-adapted organisms
J. Cell Sci.,
July 15, 2003;
116(14):
2875 - 2883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Nilsson, D. J. Kelleher, Y. Miao, Y. Shao, G. Kreibich, R. Gilmore, G. von Heijne, and A. E. Johnson
Photocross-linking of nascent chains to the STT3 subunit of the oligosaccharyltransferase complex
J. Cell Biol.,
May 26, 2003;
161(4):
715 - 725.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|